Phenformin inhibits proliferation, invasion, and angiogenesis of cholangiocarcinoma cells via AMPK-mTOR and HIF-1A pathways
- 7 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 393 (9), 1681-1690
- https://doi.org/10.1007/s00210-020-01885-3
Abstract
Phenformin (Phen), a potent activator of AMPK, is effective against some resistant cancers. This study evaluated the inhibition of proliferation, migration, invasion, and angiogenesis by Phen in aggressive cancer cells and investigated the underlying mechanism of the inhibition. Cholangiocarcinoma (CCA) KKU-156 and KKU-452 cells were used in this study. The results showed that Phen suppressed cell proliferation and induced apoptosis in both cells. Phen suppressed migration and invasion of cancer cells in wound healing and transwell chamber assays, respectively. The effects were associated with depletions of glutathione (GSH) and decreased glutathione redox ratio which represents cellular redox state. The redox stress was linked with the loss of mitochondrial transmembrane potential, as evaluated by JC-1 assay. The effect of Phen on angiogenesis was performed using HUVEC cultured cells. Phen alone did not affect tube formation of HUVEC cells. However, conditioned media from CCA cell cultures treated with Phen suppressed the tube-like structure formation. The antitumor effect of Phen was associated with AMPK activation and suppression of mTOR phosphorylation, HIF-1A, and VEGF protein expression. In conclusion, Phen inhibits cell proliferation, migration, invasion, and angiogenesis probably through AMPK-mTOR and HIF-1A-VEGF pathways. Phen may be repurposed as chemoprevention of cancer.Keywords
This publication has 37 references indexed in Scilit:
- Phenformin enhances the therapeutic benefit of BRAF V600E inhibition in melanomaProceedings of the National Academy of Sciences of the United States of America, 2013
- AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells?Biochemical Society Transactions, 2013
- Phenformin as prophylaxis and therapy in breast cancer xenograftsBritish Journal of Cancer, 2012
- Cancer metabolism: current perspectives and future directionsCell Death & Disease, 2012
- Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individualsBMC Cancer, 2011
- Redox modulation and human bile duct cancer inhibition by curcuminFood and Chemical Toxicology, 2010
- Targeting the mTOR Signaling Network for Cancer TherapyJournal of Clinical Oncology, 2009
- Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancerOncogene, 2006
- Molecular Mechanisms Activating the Nrf2-Keap1 Pathway of Antioxidant Gene RegulationAntioxidants and Redox Signaling, 2005
- Pharmacokinetic Optimisation of Oral Hypoglycaemic TherapyClinical Pharmacokinetics, 1991